Healthcare Sector Review: Meridian Settles, VIVUS down

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

CryoLife, Inc. (NYSE:CRY): Sees 2012 revenue $126M-$129M vs. consensus $128.01M

The shares closed at $5.98, up $0.49, or 8.93%, on the day. Its market capitalization is $168.27 million.

VIVUS, Inc. (NASDAQ:VVUS): The Street’s Adam Feurestein says the move down may be related to comments made by an FDA representative at an investor conference.

The shares closed at $11.18, down $0.81, or 6.76%, on the day. Its market capitalization is $993.70 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) continues to advance BCX4161, a potent inhibitor of kallikrein for potential development as an oral, prophylactic treatment for hereditary angioedema to be ready to file for first-in-human studies during the second half of 2012. BioCryst continues to enroll patients in the ongoing Phase 3 efficacy study of the influenza antiviral i.v. peramivir. The Company plans to provide an update following the planned interim analysis, which has been amended to include an assessment of futility as well as a change in timing.

The shares closed at $4.00, down $0.11, or 2.68%, on the day. Its market capitalization is $180.85 million.

Johnson & Johnson (NYSE:JNJ): Jurors in New Jersey found that Risperdal was not a substantial factor in Nebraska man’s diabetes, Bloomberg reports.

The shares closed at $64.92, up $0.27, or 0.42%, on the day. Its market capitalization is $177.29 billion.

Pfizer Inc. (NYSE:PFE): and Mylan (NASDAQ:MYL) announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis (NYSE:SNY) that will resolve pending patent litigation related to Intelliject’s 505(NYSE:B)(2) new drug application for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis. According to the terms of the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than Nov. 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration. Additional terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

The shares closed at $21.33, up $0.22, or 1.04%, on the day. Its market capitalization is $163.96 billion.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:
Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business